EYPT halted on Oct 19 2026 at $2.99
EYPT0.0%on Mon Oct 19 2026
EyePoint, Inc. Common Stock was up 0.0% on the day at $2.99, ranked #365 on — its usual five-minute volume, when TapeRank recorded this trading halt at 06:55 ET during the pre-market session when it was halted. TapeRank recorded 2 events for EYPT that day, between 06:55 and 07:48 ET, and each is in the timeline below.
THE DAY ON THE LIST · 2 EVENTS
- 06:55 ETHALT · PRE-MARKET
HALTED AT $2.99 · · 0.0% ON THE DAY · — 5M RVOL · RANK #365
No verdict was committed for this event.
THE ROW AND SESSION LEVELS AT 06:55 ET
LAST2.99DAY· 0.0%5 MIN· 0.00%5M RVOL—5M $VOL—FLOAT*86.2MRANK#365SESSIONPRE-MARKETVWAP2.99HOD3.01LOD2.98OR HIGH—OR LOW—PREV CLOSE2.99PM HIGH3.01PM LOW2.98GAP· 0.00% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 07:48 ETMOVER · PRE-MARKET
$0.7200 · ▼ 75.9% ON THE DAY · 826× 5M RVOL · RANK #2
JUSTIFIEDCONFIDENCE5/5EyePoint fell 72.9% after its pivotal LUCIA Phase 3 trial failed to achieve the primary endpoint of non-inferiority. The severe pre-market decline is proportionate to a major clinical-development setback, despite positive secondary endpoints and safety data.
WHYA 72.9% collapse, including 47.74% in five minutes, is consistent with the materiality of a pivotal Phase 3 primary-endpoint failure.ANALYZED 07:46 ET · 2 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 07:48 ET
LAST0.7200DAY▼ 75.9%5 MIN▼ 53.55%5M RVOL826×5M $VOL$511KFLOAT*86.2MRANK#2SESSIONPRE-MARKETVWAP0.8049HOD3.01LOD0.6289OR HIGH—OR LOW—PREV CLOSE2.99PM HIGH3.01PM LOW0.6289GAP▼ 78.26% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
NO VERDICT MEANS THE MODEL HAD NOT REACHED THE NAME BEFORE THE EVENT WAS FINALIZED, OR ITS ANSWER HEDGED AND WAS WITHHELD. NOTHING WAS FILLED IN AFTERWARDS.
THE SESSION
- 06:55 ETHalted (T1); resumed 07:40 ET, after 45 minutes
- 09:30 ETOpened at $0.5502, -81.6% on the previous close of $2.99
- 09:35 ETRegular-session high, $0.6000
- 11:39 ETRegular-session low, $0.4025
- 15:59 ETLast trade of the regular session, $0.4399, -85.3% on the previous close of $2.99
- Volume: 157.0M shares in regular hours, 23.3M before the open
EyePoint opened at $0.5502 after a premarket halt at $2.99, briefly reached $0.6000, then fell to an intraday low of $0.4025 by 11:39 ET and ended the regular session at $0.4399, down 85.3% from the previous close. TapeRank read the move as justified by the company’s report that its pivotal LUCIA Phase 3 trial for Duravyu failed to achieve its primary endpoint, despite positive secondary endpoints and safety data; the halt resumed at 07:40 ET, and the stock was later recorded at $0.7200 and ranked #2.
WRITTEN MON OCT 19 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 07:35 ETTrading Halt: Halt status updated at 7:35:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga
- 07:07 ETEyepoint Says Topline Results From Lucia Phase 3 Trial Of Duravyu (Vorolanib Intravitreal Insert) For Wet Age-Related Macular Degeneration Did Not Achieve The Primary EndpointBenzinga
- 07:05 ET8-K — Other Events; Financial Statements and ExhibitsSEC 8-K
- 06:55 ETTrading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News PendingBenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list